Navitus Statement on the Consolidated Appropriations Act of 2026

The Consolidated Appropriations Act of 2026, approved by Congress and signed into law this week by President Trump, includes new federal requirements to strengthen transparency, accountability and reporting across the pharmacy benefits industry.

The requirements include ensuring that plan sponsors and members have clearer insight into how prescription drug costs are managed, how rebates and fees flow through the system and how PBMs support access to affordable medications.

Navitus welcomes these changes and stands ready to support more. Transparency and full pass-through of rebates have been at the core of our business model from the beginning. Because we already return 100% of negotiated discounts to our clients, and because we don’t create additional margin through spread pricing, we are well aligned with the spirit and the letter of the new federal law.

But we must do more as an industry and a country to achieve full transparency throughout the drug supply chain. Already, Navitus leads the way with Lumicera, our cost-plus specialty pharmacy. But it’s time for our industry and nation to come together and support measures beyond this law to help people afford their medications and understand their price.

With more than 20 years of leading the way for our clients and members, we welcome the growing focus on these conversations.